<DOC>
	<DOCNO>NCT01942135</DOCNO>
	<brief_summary>The study randomize , double blind , placebo control , Phase 3 clinical trial primary objective demonstrating superiority palbociclib combination fulvestrant ( Faslodex® ) fulvestrant alone prolong PFS woman HR+ , HER2 negative metastatic breast cancer whose disease progress prior endocrine therapy . The safety two treatment arm also compare . During study treatment , pre- perimenopausal woman must receive therapy LHRH agonist goserelin ( Zoladex® generic ) .</brief_summary>
	<brief_title>Palbociclib ( PD-0332991 ) Combined With Fulvestrant In Hormone Receptor+ HER2-Negative Metastatic Breast Cancer After Endocrine Failure ( PALOMA-3 )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Palbociclib</mesh_term>
	<mesh_term>Fulvestrant</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<criteria>Women 18 year older metastatic locally advanced disease , amenable curative therapy Confirmed diagnosis HR+/HER2 breast cancer Any menopausal status Progressed within 12 month prior adjuvant progress within 1 month prior advanced/metastatic endocrine breast cancer therapy On LHRH agonist least 28 day , pre/perimenopausal , willing switch goserelin ( Zoladex ® ) time randomization . Measurable disease define RECIST version 1.1 , boneonly disease Eastern Cooperative Oncology Group ( ECOG ) PS 01 Adequate organ marrow function , resolution toxic effect prior therapy surgical procedure Patient must agree provide tumor tissue metastatic tissue baseline Prior treatment CDK inhibitor , fulvestrant , everolimus , agent inhibits PI3KmTOR pathway Patients extensive advanced/metastatic , symptomatic visceral disease , know uncontrolled symptomatic CNS metastasis Major surgery anticancer therapy within 2 week randomization Prior stem cell bone marrow transplantation Use potent CYP3A4 inhibitor inducer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Palbociclib ( PD-0332991 )</keyword>
	<keyword>Fulvestrant</keyword>
	<keyword>Goserelin</keyword>
	<keyword>Hormone receptor-+</keyword>
	<keyword>HER2-negative</keyword>
	<keyword>Prior Endocrine treatment</keyword>
	<keyword>menopausal status</keyword>
	<keyword>PALOMA-3</keyword>
</DOC>